Type Biomarker testing was evaluated during the first 3 months after the advanced cancer diagnosis. Biomarkers examined included ALK , EGFR , ROS1 , BRAF , and PD-L1. In addition to individual biomarker testing rates, we also assessed receipt of
Search Results
Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong
overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation–Positive Non–Small Cell Lung Cancer With Acquired Resistance to First- or Third
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation–Positive Non–Small Cell Lung Cancer With Acquired Resistance to First- or Third
Tanios Bekaii-Saab
The advent of biologic agents such as those that target the epidermal growth factor receptor (EGFR) has favorably impacted outcomes for patients with metastatic colorectal cancer (mCRC). An important downstream component of EGFR is the RAS
Sensitizing EGFR Mutation or Have Never Smoked Principal Investigator: Joseph Treat, MD Condition: Stage IV nonsquamous non–small cell lung cancer Institution: Fox Chase Cancer Center Patients with non–small cell lung cancer (NSCLC) who harbor an EGFR
overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor-Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
are suboptimal. Targeted treatment with anti-BRAF agents plus anti-EGFR antibodies/chemotherapy have shown promising results based on a smaller number of studies. Here we report a pooled estimate of clinical activity of anti-BRAF agents plus anti-EGFR
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD
